PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK) Files An 8-K Other Events
Item 8.01 Other Events.

On October 2, 2018, Paratek Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration approved NUZYRA™ (omadacycline), a once-daily intravenous and oral antibiotic, for the treatment of adults with community-acquired bacterial pneumonia and acute skin and skin structure infections.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Paratek Pharmaceuticals, Inc. Exhibit
EX-99.1 2 prtk-ex991_31.htm EX-99.1 prtk-ex991_31.htm Exhibit 99.1     Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)   – Modernized Tetracycline for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) specifically designed to overcome tetracycline resistance –   – First and only once-daily IV and oral antibiotic approved to treat both CABP and ABSSSI patients in nearly 20 Years –   – US launch expected first quarter 2019 –   BOSTON,…
To view the full exhibit click here

About PARATEK PHARMACEUTICALS, INC. (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company’s sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company’s other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.